Seres Therapeutics, a Cambridge, MA based biotechnology company has received Breakthrough Therapy Designation status for its lead product candidate, SER-109 from the U.S. FDA for the prevention of recurrent Clostridium difficile infection (CDI) in adults. CDI is one type of healthcare-associated infections caused by the germ C. difficile and recurrent CDI is a life-threatening condition. Patients who take antibiotics and are hospitalized are at high risk for this infection. SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated) is the lead Ecobiotic microbiome product developed by the company’s technology platform and is a combination of a small number of selected discrete organisms that work by catalyzing a shift from a disease state to one of health. Currently, Seres is conducting a Phase II clinical study to assess the efficacy and safety of SER-109 in prevention of recurrent CDI.